Therapeutic Response

PD-L1 >= 50%, Wild type ALK, and Wild type EGFR status confers therapeutic sensitivity to Atezolizumab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Atezolizumab 840mg Monotherapy - 14 Day. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 840 mg as a monotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells (TC) or >= 10% tumor-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.
Atezolizumab 840mg Monotherapy - 14 Day. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 840 mg as a monotherapy for reimbursement as a treatment option for the adjuvant treatment following complete resection and platinum-baesd chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumors have PD-L1 expression on >= 50% of tumor cells and who do not have EGFR mutant or ALK-positive mutations.
Atezolizumab 1680mg Monotherapy - 28 Day. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680mg) as a monotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a PD-L1 expression >= 50% tumor cells (TC) or >= 10% tumor-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.
Atezolizumab 1680mg Monotherapy - 28 Day. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab (1680mg) as a monotherapy for reimbursement as a treatment option for the adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on >= 50% tumor cells and who do not have EGFR mutant or ALK-positive NSCLC.
Tecentriq (atezolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized atezolizumab for the adjuvant treatment following complete resection and platinum-based chemotherapy of adult patients with non-small cell lung cancer with a high risk of recurrence whose tumors have PD-L1 expression on >= 50% of tumor cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.
Tecentriq (atezolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells or >= 10% tumor-infiltrating immune cells (IC) and who do not hvae EGFR mutant or ALK-positive NSCLC.
Atezolizumab Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 1200mg as a monotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression >= 50% tumor cells (TC) or >= 10% tumor-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.
Atezolizumab Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 1200mg as a monotherapy for reimbursement as a treatment option for the adjuvant treatment following complete resection and platinum-baesd chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumors have PD-L1 expression on >= 50% of tumor cells and who do not have EGFR mutant or ALK-positive mutations.